W. Hart, MD, PhD; BH. Ch. Stricker, MB, PhD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Flutamide (4'-nitro-3'-trifluoromethyl-isobutyranilide is an antiandrogen without estrogenic, antiestrogenic, progestational, antiprogestational, androgenic, adrenocortical, and antigonadotropic activities. The drug is an anilide that appears to block the activity of dihydrotestosterone on androgen receptors in prostatic tissue. Jaundice after 1 to 3 months of flutamide therapy during clinical trials (1-3) and fatal liver failure in the setting of flutamide treatment have been reported (4), but, with one exception, no details were given. We report a case of cholestatic hepatitis associated with flutamide therapy.
Transurethral prostatectomy was done in a 79-year-old man because of a poorly differentiated adenocarcinoma. Serum liver-enzyme and
Hart W, Stricker BC. Flutamide and Hepatitis. Ann Intern Med. 1989;110:943–944. doi: https://doi.org/10.7326/0003-4819-110-11-943_2
Download citation file:
Published: Ann Intern Med. 1989;110(11):943-944.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use